effect of propolis in COVID-19

Phase 3

• Conditions: Covid-19.; Other coronavirus as the cause of diseases classified elsewhere; U07.1

• Registration Number: IRCT20200326046868N1
• Lead Sponsor: Abadan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Patients aged 18 to 65 years
Laboratory confirmation of Covid-19 (2019-nCoV Real-Time RT-PCR)

Exclusion Criteria

Pregnancy and lactation, a history of allergies to honey and bee products, uncontrolled underlying disease including neuropsychiatric problems, diabetes, thyroid disorders, heart disease, chronic liver or kidney failure, and autoimmune diseases.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cough. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Oxygen saturation. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Respiratory rate. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Body temperature. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;LI-6. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;TNF alpha. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;Crp-hs. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;CBC. Timepoint: First and 30 days after the intervention. Method of measurement: Cell counter.